Drugmakers pledge to spend over $350B in U.S., WSJ reports

GSK (GSK) and Eli Lilly (LLY) are the latest drugmakers to reveal plans to build new manufacturing plants and other operations in the U.S., a move that aims to partly mitigate the threat of tariffs, Peter Loftus of The Wall Street Journal reports. According to the Journal’s tally of company announcements, more than a dozen drugmakers this year have pledged to spend over $350B in the U.S. by the end of the decade.